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Anaphylaxis is the most severe form of an allergic reaction. The Finnish National 
Anaphylaxis Registry has been collecting data of severe allergic reactions since year 2000 (1). Here 
we summarize a total of 1442 reported anaphylactic cases between 2000 and 2017 and identify and 
report changes in provoking agents as well as characterize the symptoms and treatments over the 
full Registry period.  
  The data is based on voluntary reports of systemic allergic reactions filed by hospital 
personnel and covering the Finnish population of 5.5 million people. A questionnaire or an online 
electronic form were used for reporting. Children (<16y) represented 663 (46%) cases (Table 1) with 
the highest frequency of reports (336 cases, 23%) accumulating from small children under school 
age (<6y)(Suppl. Figure 1). Males accounted the majority (61%) of anaphylactic reports in children, 
whereas females dominated among adults (64%) (Suppl. Figure 1).   
   The most frequently reported provoking allergens were foods (811 cases, 56%), drugs 
(365 cases, 25%) and insect venoms (90 cases, 6%) in concordance with earlier reports of 
anaphylactic elicitors (2,3). However, the Finnish Anaphylaxis Registry revealed significantly less 
reported cases due to insect stings both in children and adults compared to the European 
Anaphylaxis Registry (Fig 1A) (2). Furthermore, severe allergic reactions due to immunotherapy were 
reported in 121 (8%) cases. Other causative agents were involved in 48 (3%) patient cases, and 
without knowledge of a potential triggering allergen anaphylaxis affected 21 (1.5%) patients.   
Food triggered 502 (76%) anaphylaxis in children, of which the six most frequent 
elicitors remained the same over the Registry period (i.e. milk, wheat, eggs, nuts, fruits and fish). 
Intriguingly, the amount of anaphylaxis due to nuts significantly increased during the past five years, 
mostly due to increase in reported cases with peanut and cashew nut (Supplemental Figure 2A and 
B). The increase in nut exposure and in particularly cashew could be explained by increase in 
importation and simultaneous decrease in retail price (4). Furthermore, cashew has become a 
substituting nut for more expensive nuts or seeds in many foods, hence, providing cause for 
accidental exposures. Nonetheless, no increase in nut provoked anaphylaxis in adults was observed. 
This article is protected by copyright. All rights reserved. 
134 (27%) cases of food-triggered anaphylaxis in children were due to accidental exposure to a 
known allergen. To that end, we analyzed the places of accidental food exposures and noticed 
decrease in events in daycare centers or schools and increase at home and leisure time 
(Supplemental Figure 2C). Overall, the food-triggered anaphylaxis among pediatric patients occurred 
mostly at private homes (47%), daycare centers and schools (16%), and leisure time (14%). These 
data indicate slightly higher frequency of anaphylaxis in daycare centers and schools compared to 
earlier European reports (5).  Most likely the differences in warm meal catering services for children 
between European countries play a significant role in the observation.  
In adults the most common causes of anaphylaxis were foods (39%) and drugs (39%) 
(Table 1). Nuts, fruits and wheat were the most reported food elicitors, and antibiotics, contrast 
media and analgesics the most frequent drug elicitors (Table 1). No significant changes in eliciting 
allergens, location of anaphylaxis events or symptoms were observed among adult patients during 
the Registry period.    
Insect venom caused 38 (6%) anaphylaxis in children and 53 cases (7%) in adults. 
Anaphylaxis due to bee sting was rare (0% in children and 0,5% in adults). The lower frequency of 
hymenoptera anaphylaxis compared to European reports (5) may be due to shorter summers or 
differences in the colliding habitats of the insects and humans in countries with low population 
density. A recent registry-based report on anaphylaxis associated deaths in Finland, however, 
identified hymenoptera venoms as major cause of fatal cases (6). Only one report of fatal 
hymenoptera anaphylaxis was collected to the Registry, indicating a significant lack of reports from 
the fatal cases.  
Therapeutic  allergen products comprised 8% of the reported cases in the Registry. 
Immunotherapy (IT) to birch pollen was better tolerated than timothy (Table 1).  Only 2 cases of 
anaphylaxis due to hymenoptera IT were reported. No reports of Sublingual IT were received.  
  Symptoms in skin and in respiratory system were involved in most cases (87% and 
79%, respectively). Most frequent allergic symptoms in skin were urticaria (59%), angioedema (48%) 
and pruritus (47%). Most common respiratory symptoms were difficulty to breath (65%), wheezing 
(28%), swelling of upper airways (24%), cough (21%) and hoarse voice (19%). Gastrointestinal system 
was affected in 45% of patients and 43% had cardiovascular symptoms.  
The use of adrenalin in Finnish health care has been frequent throughout the Registry 
period (75%) and exceptionally high compared to the average of European countries (Fig. 1B) (2,7). 
Similarly, corticosteroids and antihistamines were also used more often than in the other European 
countries (Figure 1B). To further asses the self-usage of an adrenalin injector, we asked the presence 
of prescription for and usage of an auto-injector. In year 2017 27% of the cases had a prescription 
for an auto-injector but only 28% of those patients had self-injected adrenalin.  
   The Finnish Anaphylaxis Registry and the present study also have some limitations. 
The level of information filled into the questionnaires showed variation and not all the factors or 
cofactors were always reported in desired detail. The data received by voluntary reports represents 
only an unknown percentage of the actual cases of anaphylaxis over period when hospitalizations 
due to anaphylactic reactions in general have increased (8). Overall, the volunteer based reporting of 
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anaphylaxis deaths has been incomplete. In addition, seasonal trends, such as publicity of an 
allergen, may influence on the number of reports.  
In conclusion, during the 18-year registry period increase in nut caused anaphylaxis 
was observed as a new arising trend in children. Importantly, the cases of accidental food allergen 
exposures at daycare centers and schools decreased during the past ten years, overlapping with the 
period of Finnish Allergy Program (2008-2018) that aimed at endorsing knowledge and treatment of 
severe allergies and adaptating a new attitude to allergy by suggesting the avoidance of low risk 
cross-reactive allergens is only mandatory (9).  
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Table 1.  
Most frequent provoking allergens  
 Children, <16 y Adults All 
Eliciting allergen  n % n % n % 
 663 46.0  
(of total) 
779 54.0 
(of total) 
1442 100.0 
Food  502 75.7 309 39.7 811 56.2 
Nuts 136 20.5 58 7.4 194 13.5 
Milk 114 17.2 13 1.7 127 8.8 
Egg 73 11.0 4 0.5 77 5.3 
Wheat 72 10.9 33 4.2 105 7.3 
Fruits 32 4.8 35 4.5 67 4.6 
Cereals (not wheat)* 16 2.4 23 3.0 39 2.7 
Fish 13 2.0 11 1.4 24 1.7 
Seeds 10 1.5 17 2.2 27 1.9 
Soya 8 1.2 13 1.7 21 1.5 
Crustaceans 3 0.5 16 2.1 19 1.3 
Drugs 59 8.9 306 39.3 365 25.3 
Antibiotic 24 3.6 79 10.1 103 7.1 
Contrast media 3 0.5 59 7.6 62 4.3 
Analgesics 16 2.4 46 5.9 62 4.3 
Muscle relactant 1 0.2 34 4.4 35 2.4 
Local anesthetic 2 0.3 14 1.8 16 1.1 
Insect Venoms 38 5.7 53 6.8 91 6.3 
Wasps 34 5.1 44 5.6 78 5.4 
Bee 0 0.0 4 0.5 4 0.3 
Immunotherapy 44 6.6 77 9.9 121 8.4 
Birch 12 1.8 26 3.3 38 2.6 
Timothy 32 4.8 54 6.9 86 6.0 
*) Other  cereals include: oat, rye, barley, corn, rice, buckwheat and millet 
) % of children cases 
) % of adult cases 
Details of rare eliciting allergens not included 
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Figure legends 
Figure 1. Major elicitors and treatments of anaphylaxis in Finland. A) Percentages of reported severe 
allergic reactions elicited by drug, insect venom and food allergens in Finnish Anaphylaxis 
Registry compared to the European Anaphylaxis Registry.  B) Frequency of reported adrenaline, 
antihistamine and corticosteroid treatments for severe allergic reactions in Finland compared 
to the European Anaphylaxis Registry. 
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